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Abstract
The self-organization of C60 fullerene and cisplatin in aqueous solution was investigated using the computer simulation, dynamic
light scattering and atomic force microscopy techniques. The results evidence the complexation between the two compounds. The
genotoxicity of С60 fullerene, Cis and their complex was evaluated in vitro with the comet assay using human resting lymphocytes
and lymphocytes after blast transformation. The cytotoxicity of the mentioned compounds was estimated by Annexin V/PI double
staining followed by flow cytometry. The results clearly demonstrate that water-soluble C60 fullerene nanoparticles (0.1 mg/mL) do
not induce DNA strand breaks in normal and transformed cells. C60 fullerene in the mixture with Cis does not influence genotoxic
Cis activity in vitro, affects the cell-death mode in treated resting human lymphocytes and reduces the fraction of necrotic cells.
Introduction
The water-soluble inorganic bi-valent platinum derivative,
cisplatin (cis-[Pt(II)(NH3)2Cl2], Cis), is currently one of the
most effective therapeutic agents used against cancer deceases,
in particular, ovarian cancer, bladder cancer, esophagus cancer,
lung cancer, and cancer of head and neck [1]. As an antitumor
metal-containing agent Cis exerts an alkylating action and binds
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covalently to DNA. In tumor cells Cis induces the selective
inhibition of DNA synthesis and replication [2]. However, the
action of Cis is accompanied by side effects that limit the use of
Cis in anticancer chemotherapy. Сіs-induced nephro-, hepato-
and cardiotoxicity, as well as disorders of the central nervous
system and sensory organs were reported [1]. Hence, there is a
search for new drugs including nanodimensional compounds
that could lower the side effects of Cis action, deliver Cis to the
region of pathological process in a targeted manner, manage the
curing at cell level, increase solubility in bioavailable form and
protect Cis from degradation [3-9]. The carbon allotrope
С60 fullerene could act as such a potent agent.
Pristine C60 fullerenes have no acute or sub-acute toxicity in
vitro [10-12] and in vivo [13] (at least at low physiological con-
centrations), exerting strong antioxidant properties due to their
high activity as free radical acceptors [14,15]. Water-soluble
pristine С60 fullerenes penetrate through plasma membranes
and are located in the central part of tumor cells [16]. Thereby,
C60 fullerenes can be used for treatment of cancer [17,18], in-
cluding combination chemotherapy [19] and photodynamic
therapy [20-22]. They are also applied for the targeted delivery
of drugs into tumor cells [23-25].
However, there are several conflicting reports in the literature
regarding the genotoxicity of C60 fullerene [26]. Thus, a strong
correlation between the genotoxic response and the concentra-
tion of an aqueous suspension of nC60 (178 nm in size) was ob-
served at 2.2 µg/L in human lymphocytes using a single-cell gel
electrophoresis assay [27]. In contrast, with stable C60 fullerene
suspensions in 0.1% carboxymethylcellulose sodium or 0.1%
Tween 80 aqueous solution no positive mutagenic response was
observed up to the dose of 1 mg/plate with any tester strain in
the bacterial genotoxicity tests in vitro and in vivo [28].
The aqueous suspension of C60 fullerenes caused positive
responses in two bacterial genotoxicity tests, namely the
Bacillus subtilis Rec-assay and umu test, up to concentrations of
0.048 mg/L and 0.43 mg/L, respectively. In [29], bulky DNA
adducts could not be found by 32P-postlabeling/polyacrylamide
gel electrophoresis assay, suggesting that an aqueous suspen-
sion of C60 fullerenes has the potential to damage DNA. By use
of a comet assay it was also demonstrated that an aqueous
suspension of C60 fullerenes (0.1–1 mg/L) causes a concentra-
tion-dependent increase in DNA strand breaks in haemocytes
[30].
The in vivo genotoxicity of C60 fullerene was estimated with a
comet assay in lung cells of rats. After a single and repeated
instillation inflammatory responses were observed in the lungs,
suggesting that C60 fullerene has no potential for DNA damage
even at inflammation causing doses [31]. Thus, it may be con-
cluded that the genotoxicity of C60 fullerene in vitro and in vivo
systems may strongly depend on its concentration in
biomedium, dose administration, type of cells and time of expo-
sure.
Since the biological action of C60 fullerene significantly differs
from the action of traditional drugs by the mechanism of pene-
tration inside cells and biodistribution [23-25,32-35], the conju-
gation of С60 molecules with drugs is currently considered a
perspective biomedical strategy. The formation of a stable non-
covalent nanocomplex of С60 fullerene with doxorubicin
(C60+Dox) in aqueous solution was confirmed theoretically and
experimentally [23,34,36]. The antitumor action of the
C60+Dox nanocomplex was reported to be stronger than the
sole action of Dox or С60 fullerene in vivo [23,24]. Moreover,
recently it was found that C60 fullerene in C60+Dox nanocom-
plex prevents cyto- and genotoxic effects of Dox on lympho-
cytes in vitro [37,38]. Based on these results it was suggested
that the mechanism of complexation could induce biological
synergy for other drugs administered together with
C60 fullerene as well [19,23]. Taking into account the impor-
tance of Cis in chemotherapy of cancer, this drug could be a
candidate molecule for study. A recent extended physico-chem-
ical study has confirmed the formation of non-covalent entropi-
cally driven nanocomplexes between Cis and C60 fullerene in
physiological solution (i.e., the adsorption of Cis in
C60 fullerene clusters) [25,39]. Hence, it is reasonable to expect
the biological interaction of these drugs. In order to testify this
hypothesis in the present study we evaluated and compared in
vitro cytotoxic action of C60 fullerene, Сіs and their complex on
lymphocytes from healthy persons, as well as their genotoxic
effects towards resting lymphocytes and lymphocytes after blast
transformation.
Experimental
Materials preparation
A highly stable reproducible aqueous colloid solution of pris-
tine C60 fullerene (C60FAS) with a maximum concentration of
0.15 mg/mL was prepared according to the protocol [40,41].
The initial stock solution of Cis (“Сisplatin-TEVA”, Pharma-
chemie B.V.) was prepared with a concentration of 0.5 mg/mL
and was further diluted to the required concentrations used in
particular experiments.
Immobilization of Cis on С60 fullerene was accomplished ac-
cording to the following protocol: C60FAS and Cis solution
were mixed in a molar ratio of 1:2.4 (typically 0.1 mM
С60 fullerene and 0.24 mM Cis). The obtained mixture was sub-
jected to ultrasonic treatment in dispersant for 20 min, followed
by magnetic stirring over 12 h at room temperature.
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Computer simulation
The spatial structure of the C60 fullerene was built according to
[http://www-jmg.ch.cam.ac.uk/data/molecules/misc/c60.html].
The spatial structure of Cis was built with the aid of Hyper-
Chem 8.0 according to Wysokiński et al. [42] and then opti-
mizated in Gaussian 09W at the mPW1PW hybrid level of
theory [43] in LanL2DZ basis set [44]. This level of theory and
basis set is considered to be optimal for quantum-mechanical
calculations of the molecules containing platinum atoms, in par-
ticular for Cis [42]. The spatial structure of the C60+Cis
nanocomplex was built according to Kostjukov et al. [45] with
the aid of the XPLOR software (version 3.851 [46] with
CHARMM27 force field). The plane of the Cis molecule was
located parallel to the surface of the C60 fullereneat a distance
of ca. 3.4 Å. Geometry optimization of the C60+Cis nanocom-
plex was accomplished by means of molecular mechanics in
X-PLOR. The modeling of the aqueous environment was
carried out by water molecules in the form of TIP3P placed in a
cubic box with a side length of 35 Å (1423 molecules).
DLS study
Measurement of the hydrodynamic size distribution was per-
formed by dynamic light scattering (DLS) on a Zetasizer Nano
ZS (Malvern Ins. Ltd) with upload of multiple narrow modes
(high resolution) at room temperature. The instrument is
equipped with a He–Ne gas laser (max. output power 5 mW)
operating at a wavelength of 633 nm. The measurements were
performed at a 173° scattering angle (NIBS technology). The
autocorrelation function of the scattered light intensity was
analyzed by the Malvern Zetasizer software.
The zeta potential was measured with a Zetasizer Nano ZS
(Malvern Ins. Ltd) using a universal dip cell in disposable
cuvettes. The Smoluchowski approximation was used to convert
the electrophoretic mobility to the zeta potential.
AFM study
The surface morphology of the particles was examined using
atomic force microscopy (AFM). AFM images were collected
using an Integra Spectra microscope (NTMDT, Russia) in the
“light” tapping mode according to the well-established proce-
dure. For the sample preparation, a drop of solution was placed
onto a pre-cleaned microscope glass slide and dried in air prior
to AFM imaging.
Cell isolation and cultivation
Human peripheral blood from healthy donors was collected into
a heparinized medical syringe. Lymphocytes were separated by
centrifugation in a density gradient (Histopaque 1077, Sigma,
USA) according to instructions of the manufacturer and washed
twice: control lymphocytes in 0.15 M NaCl, lymphocytes that
were intended for blast transformation reaction in RPMI 1640
medium. To induce the blast transformation the lymphocyte
suspension was cultivated in RPMI 1640 medium with 10%
FBS and 1000 units/mL IL-2α at 37 °C for 20 h. After cultiva-
tion the cells were washed in 0.15 M NaCl. Aliquots of the
suspension were used for cytological analysis to evaluate the
level of blast transformation (the fraction of lymphoblasts).
Incubation of lymphocytes and lymphoblasts
The cell suspension in RPMI 1640 medium (cell concentration
in the range of 1 × 105 to 5 × 105 cells per mL) was incubated
in the presence of either C60 fullerene (0.1 mg/mL), anticancer
drug Сіs (0.01, 0.1 or 0.15 mg/mL) or the complex of
C60 fullerene with Cis (Cis concentration was 0.1 or 0.15 mg/L,
the C60 fullerene to Cis molar ratio was equal to 1:2.4) for 1.5 h
at 37 °C, washed once in 0.15 M NaCl, and then used for the
comet assay. Five to seven independent repeats of the experi-
ments were performed. As shown before [25], the molar ratio of
1:2.4 yields the highest anticancer activity of the С60+Cis com-
plex and was therefore used in the experiments.
Comet assay
To obtain lysed cells (nucleoids) 20 µL of the cell suspension
was mixed with 40 µL of 1% low-melting agarose (Sigma,
USA) at ca. 37 °C. 20 µL of the mixture were used to prepare a
microscope slide previously covered with 1% high-melting
agarose. After agarose polymerization, the slides were placed in
the lysis solution consisting of 2.5 М NaCl, 100 mM ЕDTA,
10 mM Tris-HCl (рН 7.5), and 1% Triton X-100 (Ferak,
Germany), which was added before use. Cells were exposed to
lysis solution for 2 h at 4 °C. After the lysis, slides were washed
with TBE buffer (89 mM Tris-borate, 2 mM EDTA, рН 7.5)
and electrophoresed in the same buffer for 20 min at 4 °C
(1 V/cm, 300 mA).
After electrophoresis, the slides were stained with 1.3 μg/mL of
DAPI (Sigma, USA) and immediately analyzed under a fluores-
cence microscope (LOMO, Russia) connected with Canon
A570 camera (a total 200 to 300 cells on each slide were
analyzed). The relative amount of DNA in the comet tail, the
parameter that reflects the level of DNA damages, was deter-
mined using the image analysis software programs Comet
Assay IV (Perspective Instruments, UK) and CometScore
(TriTec Corp., USA).
Cell-death assay
Apoptosis was assessed by staining cells with Annexin V–fluo-
rescein isothiocyanate (FITC) and counterstaining with
propidium iodide (PI) with the use Annexin V-FITC Apoptosis
Detection Kit (Dojindo EU GmbH, Munich, Germany) accord-
ing to the instructions of the manufacturer. Briefly, 2 × 105 cells
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were placed into wells of a 96-well flat-bottom plate and were
treated with C60 fullerene (sample 1), Сіs (sample 2) and
C60+Cis nanocomplex (sample 3) for 24 h. All additives were
used at the concentration of 0.15 mg/mL. Untreated cells were
used as a control (sample 4). Afterwards cells were washed
twice with PBS and incubated in the Annexin V binding buffer
containing 1/50 volume of FITC-conjugated Annexin V solu-
tion and PI (50 µg/mL) for 10 min at room temperature in the
dark. Cells from each sample were then analyzed by FacsCal-
ibur flow cytometer (BD Biosciences). The data were analyzed
using CELLQuest software (BD). PI detects cells that have lost
CPM integrity (i.e., necrotic and secondary necrotic cells),
whereas Annexin V detects early apoptotic cells.
Statistics
Statistical analysis was performed by conventional methods of
variation statistics. Significance of the differences between the
control and experimental measurements was estimated within
the framework of the Student’s t-test using Origin 8.0 software
(OriginLab Corporation, USA). The difference between the
compared values was considered to be significant at p < 0.05.
Results and Discussion
Characterization of the C60+Cis mixture
The freshly prepared mixture of C60 fullerene with Cis was
characterized by conventional physico-chemical methods,
namely DLS and AFM. The monitoring of the morphology of
nanoparticles in solution is important not only for checking the
quality of solution for study, but also to control the degree of
aggregation which may influence their biodistribution and
toxicity [47].
Figure 1 shows DLS data of C60FAS and C60+Cis mixture at
room temperature. It is seen that C60FAS contains C60 fullerene
nanoparticles with hydrodynamic sizes ranging from 65 to
105 nm. The C60+Cis nanocomplex exhibits hydrodynamic
sizes from 91 to 164 nm. The Z-average size of the C60+Cis
nanocomplex is about 122 nm. These results are in accordance
with AFM data (Figure 2), as well as with previous study of
C60+Cis complexation [39].
The zeta potential of the C60+Cis mixture measured in this
work equals to −16.8 mV at room temperature. It is known from
previous studies that C60 fullerene clusters not containing any
guest molecules have a zeta potential equal to −23 mV in water
solution [41]. Addition of neutral Cis molecules into C60FAS
results in their adsorption into the C60 fullerene clusters and
causes a lowering of the absolute value of the zeta potential.
The stability of such negatively charged clusters in water is de-
termined by two opposite forces, viz., electrostatic repulsion of
negatively charged C60 molecules and attraction of the
Figure 1: DLS (hydrodynamic size) results of C60FAS (grey; concen-
tration 0.15 mg/mL) and C60+Cis mixture (red; molar ratio of 1:2.4).
Figure 2: AFM images of a) nanoparticles in C60FAS (concentration
0.15 mg/mL) and b) C60+Cis mixture (molar ratio as 1:2.4).
C60 fullerenes due to hydrophobic and van der Waals forces.
Thereby, the negative potential of C60+Cis clusters is an impor-
tant factor responsible for the stabilization of this aqueous
system.
The structural and energetic peculiarities of C60+Cis complex-
ation were investigated by calculating the energy-minimized
spatial structure of their complex, shown in Figure 3.
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Figure 5: The relative amount of DNA in the comet tails (P) after 20 min of electrophoresis of a) lymphocytes and b) lymphoblasts treated with Cis,
C60 fullerene or C60+Cis nanocomplex. Control: cells were incubated in RPMI 1640 medium without any additional agents. The average values of 5–7
independent experiments are presented. The error bars represent the standard deviations. *Statistically significant (p < 0.05) with respect to control
cells.
Figure 3: The calculated energy-optimized structure of the C60+Cis
nanocomplex in aqueous solution.
The initial location coordinates of Cis above the C60 fullerene
surface were taken from the ab initio structure [39]. Then we
performed the molecular dynamics simulation of this nanocom-
plex in aqueous environment and calculated the time-averaged
energies of interaction. The net van der Waals, electrostatic
and hydrophobic energies were obtained as follows, ΔGvdw ≈
−0.6 kJ/mol, ΔGel ≈ 0.9 kJ/mol and ΔGhyd ≈ −9.0 kJ/mol, re-
spectively. The near-zero magnitudes of the net ‘vdw’ and ‘el’
terms are quite expected and originate from compensatory
nature of the enthalpic interaction with water environment and
between the interacting molecules (discussed in more detail in
[36,39]). The ‘hyd’ term outweighs any other interactions indi-
cating the predominantly entropic character of C60+Cis com-
plexation. The obtained results fully agree with previous calori-
metric measurements of the same system [39] reporting the
purely hydrophobic nature of interaction between these mole-
cules. Moreover, the same conclusion was made regarding the
aggregation of C60 fullerene in solution [48], C60 fullerene
complexation with Dox [36] and landomycin A [49], and seems
to reveal a general pattern of complexation of small molecules
in water [45].
Estimation of genotoxic effects
Figure 4 shows typical images of the comet assay obtained after
20 min of electrophoresis of lysed cells. For both lymphocytes
and lymphoblasts, either the control cells or cells treated with
the agents studied, we did not observe any differences in the
comet appearance.
Figure 4: The representative comet-assay images obtained after
20 min of electrophoresis of a) control cells, b) cells incubated with
C60 fullerene at concentration of 0.1 mg/mL, and c) cells treated with
Cis at 0.15 mg/mL. The bars correspond to 10 µm.
The average amount of DNA in the comet tails in control exper-
iments, when the isolated lymphocytes or lymphoblasts were in-
cubated in RPMI 1640 medium without any agents, was ca.
0.11 for both cell types (Figure 5). This value, which appears to
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be slightly higher than that usually observed for intact cells (the
typical value is 0.06–0.07) [50], may indicate that a small
amount of DNA strand breaks occurred in the cells. We did not
observe any significant changes in the average amount of DNA
in the comet tails after cell treatment with C60 fullerene
(Figure 5). Thus, C60 fullerene nanoparticles do not induce the
DNA breaks in the cells.
At a low Cis concentration (0.01 mg/mL) the Cis-treated
lymphocytes and lymphoblasts showed a DNA amount in the
tails comparable to that of control cells. The same picture was
observed for lymphocytes treated with Сis at 0.1 mg/mL
(Figure 5a), but a significant decrease in the DNA fraction in
the comet tails was detected for lymphoblasts incubated with
Cis at this concentration. To explain this result it is worth
remembering the mechanism of Cis action. After penetration
into cell nuclei Cis may induce coordinate bonds between Pt
and guanine bases in DNA that leads to intra- and inter-strand
crosslinking. In addition, Cis interaction with nuclear proteins
induces DNA–protein crosslinking. After cell lysis these
crosslinks remain in nucleoids, which hamper DNA migration
in the comet tail under electrophoretic conditions, i.e., the lower
the fraction of DNA in the tail, the stronger the mutagenic
action of Cis. Thus, lymphoblasts appear to be more sensitive to
Cis action than lymphocytes. During cultivation with IL-2α
(when lymphocytes are transformed into lymphoblast) a large
set of genes are activated to allow the entry of cells in the G1
phase of the cell cycle [51]. Probably, such transformation that
never occurs in vivo in lymphocytes under normal conditions,
leads to an increase in the cells' sensitivity to the anticancer
drug Cis.
The increase of the Cis concentration up to 0.15 mg/mL causes
significant decrease in the DNA fraction in the comet tails for
both cell types, viz., the average amount of DNA in the tail was
0.08 ± 0.01 for lymphocytes and 0.05 ± 0.01 for lymphoblasts.
At the same time, we did not observe any differences in DNA
fraction in the comet tail between cells treated with Cis only or
with its nanocomplex with C60 fullerene. Hence, C60 fullerene
in the nanocomplex does not influence the Cis activity.
Comparative evaluation of the cytotoxic
effects
Genotoxic effect of Cis is mostly associated with apoptotic cell
death. However, mechanism of Cis cytotoxic action involves
multiple signaling pathways inducing not only apoptosis but
also necrotic cell death [52-55]. Nephrotoxicity is considered to
be the most important side effect of Cis and is mainly caused by
tubular epithelial cell necrosis induced by extensive reactive
oxygen species (ROS) generation [56,57]. According to Kaeidi
et al. [58], preconditioning with mild oxidative stress may en-
hance some endogenous defense mechanisms and stimulate cel-
lular adaptation to subsequent severe oxidative stress after the
treatment with Cis. C60 fullerene can either consume ROS or in-
duce their generation [59]. Taking into account this fact we
have hypothesized that C60 fullerene in the nanocomplex with
Cis can affect mode of cell death induced by Cis. In order to
testify this hypothesis, Annexin V/PI double staining of human
healthy lymphocytes treated with either C60 fullerene, Cis or
their nanocomplex was conducted. As shown in Figure 6, the
total number of dead lymphocytes from healthy persons after
the treatment with C60 fullerene was 13.8% vs 32.4% and
36.7% in samples of cells treated with Cis and C60+Cis
nanocomplex, respectively.
Figure 6: C60 fullerene, Cis and their nanocomplex induce apoptosis
as well as necrosis of lymphocytes from healthy persons. Cells were
treated with mentioned compounds at the concentration of 0.15 mg/mL
for 24 h. After culturing, cells were stained with annexin V (AnnV)/
propidium iodide (PI) and analyzed by flow cytometry. Control: cells
were incubated without any additional agents. The average values for
four independent experiments are presented. *p < 0.05 compared with
untreated cells; #p < 0.05 compared with cells treated with C60+Cis
nanocomplex.
Analysis of cell death using an Annexin V-FITC/PI assay
allows one to differentiate the stages of apoptosis and to reveal
necrotic cells. The treatment of human healthy resting lympho-
cytes with C60 fullerene resulted in significant increase of early
apoptotic cells (An+PI−) to 11.8%, and raise of late apoptotic
(An+PI+) to 1.7% on average, as well as necrotic cells
(An−PI+) to 0.3%. Apoptosis to necrosis ratio in these samples
was 6:1 (on average). In cell samples treated with Cis we
noticed significantly more necrotic cells (9.2%), wherein apo-
ptosis to necrosis ratio was 2:1. C60+Cis nanocomplex induced
mainly apoptosis in resting lymphocytes, and apoptosis to
necrosis ratio was 7:1.
Conclusion
1. The computer simulation, DLS and AFM data confirmed the
ability of C60 fullerene to form non-covalent nanocomplex with
Cis in aqueous solution.
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2. C60 fullerene nanoparticles do not induce DNA strand breaks
in the normal (lymphocytes) and transformed (lymphoblasts)
cells as revealed by the comet assay.
3. C60 fullerene in the C60+Cis nanocomplex does not influ-
ence the genotoxic activity of Cis in vitro.
4. C60 fullerene in the C60+Cis nanocomplex affects the cell
death mode in treated resting lymphocytes from healthy persons
and reduces the fraction of necrotic cells.
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